FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2589384660> ?p ?o ?g. }

• W2589384660 endingPage "23276" @default.
• W2589384660 startingPage "23265" @default.
• W2589384660 abstract "Drug resistance to sorafenib is common in patients with hepatocellular carcinoma(HCC). We examined the effects of a combination of sorafenib and fluvastatin on HCC using in vitro and in vivo models. The dual treatment induced apoptosis and reduced cellular viability in HCC more effectively than either drug alone. The combination treatment also inhibited activation of hepatic stellate cells, whereas single drug treatments did not. On a molecular level, combined treatment inhibited activation of the MAPK and NF-κB pathways via Toll-like receptor 4 in HCC cells. Combined treatment also inhibited expression of stromal cell-derived factor 1α in HCC cells, which further inhibited the MAPK pathway in hepatic stellate cells. These results suggest that a combination of sorafenib and fluvastatin may be a promising therapeutic strategy for patients with advanced HCC." @default.
• W2589384660 created "2017-03-03" @default.
• W2589384660 creator A5005920848 @default.
• W2589384660 creator A5035441361 @default.
• W2589384660 creator A5036509058 @default.
• W2589384660 creator A5040367016 @default.
• W2589384660 creator A5046070452 @default.
• W2589384660 creator A5050787253 @default.
• W2589384660 creator A5051382093 @default.
• W2589384660 creator A5063381428 @default.
• W2589384660 creator A5066221170 @default.
• W2589384660 creator A5075523709 @default.
• W2589384660 date "2017-02-21" @default.
• W2589384660 modified "2023-10-11" @default.
• W2589384660 title "Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma" @default.
• W2589384660 cites W1966799282 @default.
• W2589384660 cites W1970916626 @default.
• W2589384660 cites W1971837077 @default.
• W2589384660 cites W2003773886 @default.
• W2589384660 cites W2004422184 @default.
• W2589384660 cites W2004568092 @default.
• W2589384660 cites W2017264140 @default.
• W2589384660 cites W2032899766 @default.
• W2589384660 cites W2041906973 @default.
• W2589384660 cites W2056625657 @default.
• W2589384660 cites W2065878907 @default.
• W2589384660 cites W2071609983 @default.
• W2589384660 cites W2089875541 @default.
• W2589384660 cites W2104754475 @default.
• W2589384660 cites W2105924284 @default.
• W2589384660 cites W2111639514 @default.
• W2589384660 cites W2122750409 @default.
• W2589384660 cites W2132493831 @default.
• W2589384660 cites W2140765540 @default.
• W2589384660 cites W2148606789 @default.
• W2589384660 cites W2154725805 @default.
• W2589384660 cites W2160883099 @default.
• W2589384660 cites W2164906049 @default.
• W2589384660 cites W2220594341 @default.
• W2589384660 cites W2520809168 @default.
• W2589384660 cites W316747721 @default.
• W2589384660 cites W1955683172 @default.
• W2589384660 doi "https://doi.org/10.18632/oncotarget.15575" @default.
• W2589384660 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5410302" @default.
• W2589384660 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28423574" @default.
• W2589384660 hasPublicationYear "2017" @default.
• W2589384660 type Work @default.
• W2589384660 sameAs 2589384660 @default.
• W2589384660 citedByCount "24" @default.
• W2589384660 countsByYear W25893846602017 @default.
• W2589384660 countsByYear W25893846602018 @default.
• W2589384660 countsByYear W25893846602019 @default.
• W2589384660 countsByYear W25893846602020 @default.
• W2589384660 countsByYear W25893846602021 @default.
• W2589384660 countsByYear W25893846602022 @default.
• W2589384660 countsByYear W25893846602023 @default.
• W2589384660 crossrefType "journal-article" @default.
• W2589384660 hasAuthorship W2589384660A5005920848 @default.
• W2589384660 hasAuthorship W2589384660A5035441361 @default.
• W2589384660 hasAuthorship W2589384660A5036509058 @default.
• W2589384660 hasAuthorship W2589384660A5040367016 @default.
• W2589384660 hasAuthorship W2589384660A5046070452 @default.
• W2589384660 hasAuthorship W2589384660A5050787253 @default.
• W2589384660 hasAuthorship W2589384660A5051382093 @default.
• W2589384660 hasAuthorship W2589384660A5063381428 @default.
• W2589384660 hasAuthorship W2589384660A5066221170 @default.
• W2589384660 hasAuthorship W2589384660A5075523709 @default.
• W2589384660 hasBestOaLocation W25893846601 @default.
• W2589384660 hasConcept C126322002 @default.
• W2589384660 hasConcept C150903083 @default.
• W2589384660 hasConcept C16930146 @default.
• W2589384660 hasConcept C176891718 @default.
• W2589384660 hasConcept C185592680 @default.
• W2589384660 hasConcept C190283241 @default.
• W2589384660 hasConcept C207001950 @default.
• W2589384660 hasConcept C2776329913 @default.
• W2589384660 hasConcept C2778019345 @default.
• W2589384660 hasConcept C2778417548 @default.
• W2589384660 hasConcept C2778695046 @default.
• W2589384660 hasConcept C502942594 @default.
• W2589384660 hasConcept C53227056 @default.
• W2589384660 hasConcept C55493867 @default.
• W2589384660 hasConcept C57074206 @default.
• W2589384660 hasConcept C62478195 @default.
• W2589384660 hasConcept C71924100 @default.
• W2589384660 hasConcept C86803240 @default.
• W2589384660 hasConcept C98274493 @default.
• W2589384660 hasConceptScore W2589384660C126322002 @default.
• W2589384660 hasConceptScore W2589384660C150903083 @default.
• W2589384660 hasConceptScore W2589384660C16930146 @default.
• W2589384660 hasConceptScore W2589384660C176891718 @default.
• W2589384660 hasConceptScore W2589384660C185592680 @default.
• W2589384660 hasConceptScore W2589384660C190283241 @default.
• W2589384660 hasConceptScore W2589384660C207001950 @default.
• W2589384660 hasConceptScore W2589384660C2776329913 @default.
• W2589384660 hasConceptScore W2589384660C2778019345 @default.
• W2589384660 hasConceptScore W2589384660C2778417548 @default.
• W2589384660 hasConceptScore W2589384660C2778695046 @default.

• next